Global Fatty Liver Day 2026
Analysis based on 6 articles · First reported Jun 11, 2026 · Last updated Jun 11, 2026
The event aims to increase awareness and early detection of steatotic liver disease, which could lead to increased demand for diagnostic tools, treatments, and research funding in the healthcare and pharmaceutical industries. This could positively impact companies involved in liver disease diagnostics and therapeutics. The Global Liver Institute's efforts to mobilize a global community could also foster cross-sector collaborations, potentially leading to new partnerships and investments.
Global Fatty Liver Day 2026 is a worldwide public health campaign organized by the Global Liver Institute (GLI) to raise awareness and promote urgent action against steatotic liver disease (SLD). Building on the momentum from a landmark World Health Organization (WHO) resolution on noncommunicable diseases, the initiative emphasizes early detection, prevention, and expanded access to care for millions affected by SLD. Larry R. Holden, President and CEO of GLI, highlighted the need for coordinated, cross-sector collaboration among governments, healthcare providers, researchers, industry, and advocates. The campaign urges actions such as including SLD in national health plans, increasing research funding, implementing routine liver screenings, expanding access to noninvasive diagnostic tools, and strengthening education for clinicians and the public. Partner events are taking place globally in countries including Uganda, Mexico, Bangladesh, Turkiye, Ghana, Nigeria, Croatia, Kenya, and the United States.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard